Allogene Therapeutics, Inc. (ALLO): Price and Financial Metrics


Allogene Therapeutics, Inc. (ALLO): $24.51

-0.49 (-1.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ALLO POWR Grades


  • ALLO scores best on the Sentiment dimension, with a Sentiment rank ahead of 63.28% of US stocks.
  • ALLO's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • ALLO's current lowest rank is in the Quality metric (where it is better than 11.18% of US stocks).

ALLO Stock Summary

  • Allogene Therapeutics Inc's stock had its IPO on October 11, 2018, making it an older stock than merely 7.74% of US equities in our set.
  • ALLO's price/sales ratio is 91.74; that's higher than the P/S ratio of 96.57% of US stocks.
  • ALLO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 7.62% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Allogene Therapeutics Inc are ARWR, IMTX, ARVN, CUE, and FATE.
  • Visit ALLO's SEC page to see the company's official filings. To visit the company's web site, go to www.allogene.com.

ALLO Valuation Summary

  • In comparison to the median Healthcare stock, ALLO's EV/EBIT ratio is 145.73% lower, now standing at -13.4.
  • ALLO's EV/EBIT ratio has moved NA NA over the prior 35 months.
  • Over the past 35 months, ALLO's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ALLO.

Stock Date P/S P/B P/E EV/EBIT
ALLO 2021-08-31 88.3 3.3 -14.2 -13.4
ALLO 2021-08-30 89.4 3.4 -14.4 -13.6
ALLO 2021-08-27 90.4 3.4 -14.5 -13.8
ALLO 2021-08-26 87.9 3.3 -14.1 -13.4
ALLO 2021-08-25 89.4 3.4 -14.4 -13.6
ALLO 2021-08-24 89.9 3.4 -14.4 -13.7

ALLO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALLO has a Quality Grade of D, ranking ahead of 11.16% of graded US stocks.
  • ALLO's asset turnover comes in at 0.032 -- ranking 349th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ALLO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.032 1 -0.253
2021-03-31 0.031 1 -0.240
2020-12-31 0.000 NA -0.294
2020-09-30 0.000 NA -0.328
2020-06-30 0.000 NA -0.370
2020-03-31 0.000 NA -0.395

ALLO Price Target

For more insight on analysts targets of ALLO, see our ALLO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $48.57 Average Broker Recommendation 1.35 (Strong Buy)

ALLO Stock Price Chart Interactive Chart >

Price chart for ALLO

ALLO Price/Volume Stats

Current price $24.51 52-week high $44.92
Prev. close $25.00 52-week low $20.58
Day low $23.90 Volume 373,376
Day high $24.88 Avg. volume 986,846
50-day MA $23.21 Dividend yield N/A
200-day MA $28.71 Market Cap 3.48B

Allogene Therapeutics, Inc. (ALLO) Company Bio


Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is based in South San Francisco, California.


ALLO Latest News Stream


Event/Time News Detail
Loading, please wait...

ALLO Latest Social Stream


Loading social stream, please wait...

View Full ALLO Social Stream

Latest ALLO News From Around the Web

Below are the latest news stories about Allogene Therapeutics Inc that investors may wish to consider to help them evaluate ALLO as an investment opportunity.

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile

Editor's note: Seeking Alpha is proud to welcome Eskimo Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click here to find out more » Introduction If you are...

Eskimo Research on Seeking Alpha | September 6, 2021

Allogene Therapeutics (ALLO) Up 9.6% Since Last Earnings Report: Can It Continue?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 3, 2021

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in two upcoming virtual investor conferences. H.C. Wainwright 23rd Annual Global Investment ConferenceMonday, September 13, 20214:00AM PT/7:00AM ET BofA Global Research Global Healthcare Conference 2021Thursday, Septem

Yahoo | September 1, 2021

Fridays ETF Movers: XBI, GXC

In buying and selling on Friday, the SPDR S&P Biotech ETF (XBI) is outperforming different ETFs, up about 2.4% on the day. Elements of that ETF displaying explicit energy embrace shares of Allogene Therapeutics (ALLO), up about 13.1% and shares of TG Therapeutics (TGTX), up about 9.6% on the day. And underperforming different ETFs in [] The post Fridays ETF Movers: XBI, GXC appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

FXNews24 | August 20, 2021

Allogene's (ALLO) CAR T Therapy Gets Orphan Drug Status

Allogene's (ALLO) CAR T therapy, ALLO-715, gets orphan-drug designation in the United States. It is a potential treatment for multiple myeloma and other BCMA-positive malignancies.

Yahoo | August 13, 2021

Read More 'ALLO' Stories Here

ALLO Price Returns

1-mo 10.55%
3-mo 0.12%
6-mo -33.77%
1-year -32.50%
3-year N/A
5-year N/A
YTD -2.89%
2020 -2.85%
2019 -3.53%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7951 seconds.